drugset / Trial / NCT05023707
Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/2
Unknown
5 enrolled
The First Affiliated Hospital of Soochow University
PersonGen BioTherapeutics (Suzhou) Co., Ltd. · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe First Affiliated Hospital with Nanjing Medical University · collabThe Second People's Hospital of Huai'an · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective,open-label, phase1/2 study to evaluate the safety and efficacy of anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of FLT3 positive relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2021-12-31
- Primary completion
- 2023-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-FLT3 CAR-T | Cell therapy | — | Intravenous |